Global Chronic Cough Market, By Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, Others), Route of Administration (Oral, Injections, Inhalation, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Chronic Cough Market Analysis and Size
The global chronic cough market is expected to witness significant growth during the forecast period. Global chronic cough market is majorly driven by the high prevalence of chronic lung infections diseases as chronic cough is a very common indication. Medical advancements which involves ongoing drug discovery, and government and non-government organizational initiatives are what that boosts the market growth. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global chronic cough market in the forecast period 2022-2029. The expected CAGR of global chronic cough market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 6.15 billion in 2021, and it would grow upto USD 11.38 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Chronic cough is defined as persistent cough that long last to 6-8 weeks. The chronic cough majorly affects the life of the patients by light-headedness, interrupt sleeping, vomiting, and even rib fractures. It is caused by multiple reasons such as infections, asthma, Gastroesophageal reflux disease (GERD) among others. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Chronic Cough Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, Others), Route of Administration (Oral, Injections, Inhalation, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Merck KGaA (Germany), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Biocon (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), NeRRe Therapeutics (U.K.)
|
|
Market Opportunities
|
|
Global Chronic Cough Market Dynamics
Drivers
- Increased Initiatives by Government and Market Players
The increasing number of efforts and initiatives that are being initiated by the government and major market leaders all over the world are boosting the market growth. Governments in many countries have launched several initiatives towards launching more and more drugs for chronic cough that will help in the betterment of the patients. Thus, these factors drive the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Prevalence of Cough
According to the reports of CDC, around 25 million people had asthma in the U.S. in 2017, and it is commonly diagnosed among adult women than in men. The organization also stated that incidence of asthma was 7.8% in 2015, which rise upto 7.9% in 2017, in North America. This creates more opportunity in the market.
Restraints/Challenges
- Less Trained Professionals
Less trained individuals who are unable to handle the chronic cough patients are acting as a restrain to the market growth. Many a times, the disease might get complicated and the professionals may not understand the underlying cause pf the disease. Hence, it acts negatively to the patients amd as a result hampers the market growth.
- High Cost of Drugs
The high cost associated with the varied treatment types are working as a restraint to the market growth.
This global chronic cough market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chronic cough market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Chronic Cough Market
COVID-19 left a major impact on the global chronic cough market. Cough remedies can be used to manage cough caused as a symptom after COVID-19 exposure. Nevertheless, workforce shortages along with resource limitations, because of COVID-19 is expected to negatively impact the growth of the industry in the forecast period. There has been a abrupt growth in R&D activities to bring new products to cure cough which is expected to expand the growth of chronic cough market during the forecast period.
Global Chronic Cough Market Scope
The global chronic cough market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Antihistamines
- Corticosteroids
- Decongestants
- Combination Drug
- Antibiotics
- Acid Blockers
- Others
Route of Administration
- Oral
- Inhalational
- Injectable
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Chronic Cough Market Regional Analysis/Insights
The global chronic cough market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global expectorants market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increasing geriatric population, over use of unhealthy food and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation specific for paediatric population.
Asia Pacific dominates the market due to surge population and increase in government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chronic Cough Market Share Analysis
The global chronic cough market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global chronic cough market.
Key players operating in the global chronic cough market include:
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Biocon (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- NeRRe Therapeutics (U.K.)
SKU-